

Steven G Chrysant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2381451/publications.pdf>

Version: 2024-02-01

136
papers

3,478
citations

159358

30
h-index

168136

53
g-index

138
all docs

138
docs citations

138
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	The debate over the optimal blood pressure treatment target of less than 130/80 mmHg. <i>Postgraduate Medicine</i> , 2023, 135, 208-213.	0.9	1
2	Relatability of Blood Pressure Monitoring With Wearable Cuffless Devices. <i>American Journal of Cardiology</i> , 2022, , .	0.7	3
3	Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. <i>Hospital Practice (1995)</i> , 2022, 50, 196-202.	0.5	5
4	Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 223-232.	0.6	4
5	The pathophysiology and management of diuretic resistance in patients with heart failure. <i>Hospital Practice (1995)</i> , 2021, , 1-9.	0.5	0
6	A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 635-640.	1.0	4
7	The Debate Over Egg Consumption and Incident Cardiovascular Disease. <i>Cardiology in Review</i> , 2021, 29, 238-244.	0.6	4
8	Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 59-67.	1.0	6
9	New and emerging cardiovascular and antihypertensive drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1315-1327.	1.0	5
10	The cardiometabolic benefits of exercise in postmenopausal women. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1691-1693.	1.0	3
11	Orthostatic hypotension and cardiovascular outcomes: Should we be concerned?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2161-2162.	1.0	1
12	The current debate over treatment of subclinical hypothyroidism to prevent cardiovascular complications. <i>International Journal of Clinical Practice</i> , 2020, 74, e13499.	0.8	12
13	The clinical significance of isolated diastolic hypertension. <i>Postgraduate Medicine</i> , 2020, 132, 624-628.	0.9	11
14	Noninvasive vascular function tests for the future prediction of primary cardiovascular diseases. <i>Hospital Practice (1995)</i> , 2020, 48, 113-118.	0.5	5
15	The tilt table test is useful for the diagnosis of vasovagal syncope and should not be abolished. <i>Journal of Clinical Hypertension</i> , 2020, 22, 686-689.	1.0	7
16	In response to: an opposing point of view on the obesity paradox. <i>Postgraduate Medicine</i> , 2019, 131, 388-389.	0.9	1
17	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. <i>Hospital Practice (1995)</i> , 2019, 47, 67-72.	0.5	7
18	New noninvasive vascular tests could improve the prediction and early diagnosis and treatment of cardiovascular diseases. <i>Journal of Clinical Hypertension</i> , 2019, 21, 893-895.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 345-351.	0.6	20
20	Association of hypomagnesemia with cardiovascular diseases and hypertension. <i>International Journal of Cardiology: Hypertension</i> , 2019, 1, 100005.	2.2	19
21	Pathophysiology and treatment of obesity-related hypertension. <i>Journal of Clinical Hypertension</i> , 2019, 21, 555-559.	1.0	33
22	The single use of body mass index for the obesity paradox is misleading and should be used in conjunction with other obesity indices. <i>Postgraduate Medicine</i> , 2019, 131, 96-102.	0.9	45
23	Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. <i>Hospital Practice (1995)</i> , 2018, 46, 47-55.	0.5	7
24	Obesity is bad regardless of the obesity paradox for hypertension and heart disease. <i>Journal of Clinical Hypertension</i> , 2018, 20, 842-846.	1.0	5
25	Aggressive systolic blood pressure control in older subjects: benefits and risks. <i>Postgraduate Medicine</i> , 2018, 130, 159-165.	0.9	17
26	Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 351-355.	1.0	10
27	Authors reply: statins and new onset of diabetes: which one outweighs risk or benefit?. <i>Postgraduate Medicine</i> , 2018, 130, 147-147.	0.9	1
28	Sacubitril/valsartan: a cardiovascular drug with pluripotential actions. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 543-548.	0.7	5
29	The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 559-565.	0.6	117
30	The impact of coffee consumption on blood pressure, cardiovascular disease and diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 151-156.	0.6	32
31	New onset diabetes mellitus induced by statins: current evidence. <i>Postgraduate Medicine</i> , 2017, 129, 430-435.	0.9	37
32	New evidence for the diastolic J-curve effect challenges the safety of intensive blood pressure control. <i>Journal of Clinical Hypertension</i> , 2017, 19, 340-343.	1.0	8
33	Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 461-468.	2.3	14
34	Herbs Used for the Treatment of Hypertension and their Mechanism of Action. <i>Current Hypertension Reports</i> , 2017, 19, 77.	1.5	36
35	Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 517-523.	0.6	3
36	Treatment of Modifiable Risk Factors Is Associated With Decrease in Coronary Heart Disease Incidence: Time to Use the Polypill. <i>Journal of Clinical Hypertension</i> , 2016, 18, 840-842.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Effects of High Salt Intake on Blood Pressure and Cardiovascular Disease: The Role of COX Inhibitors. <i>Clinical Cardiology</i> , 2016, 39, 240-242.	0.7	17
38	The Clinical Significance of N-terminal Pro-Brain Natriuretic Peptide in Detecting the Residual Cardiovascular Risk in Hypertension and Other Clinical Conditions and in Predicting Future Cardiovascular Events. <i>Journal of Clinical Hypertension</i> , 2016, 18, 718-720.	1.0	5
39	Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 14.	1.5	8
40	A Healthy Lifestyle Could Reduce the Onset of First Heart Attack by 80%. <i>Journal of Clinical Hypertension</i> , 2015, 17, 168-171.	1.0	5
41	The Cardiovascular Consequences of Excess Sitting Time. <i>Journal of Clinical Hypertension</i> , 2015, 17, 528-531.	1.0	6
42	Antihypertensive therapy causes erectile dysfunction. <i>Current Opinion in Cardiology</i> , 2015, 30, 383-390.	0.8	55
43	Coffee Consumption and Cardiovascular Health. <i>American Journal of Cardiology</i> , 2015, 116, 818-821.	0.7	22
44	Association of Exposure to Bisphenol A and Incidence of Cardiovascular Disease and Hypertension. <i>Journal of Clinical Hypertension</i> , 2015, 17, 737-739.	1.0	6
45	Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. <i>Current Hypertension Reports</i> , 2015, 17, 511.	1.5	5
46	Early and sustained blood pressure control is necessary for stroke prevention. <i>Journal of Thoracic Disease</i> , 2015, 7, 1070-3.	0.6	0
47	Controversy Regarding the Association of High Calcium Intake and Increased Risk for Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2014, 16, 545-550.	1.0	20
48	Treatment of Hypertension in Patients with Atherosclerotic Renal Artery Stenosis, Updated. <i>Postgraduate Medicine</i> , 2014, 126, 59-67.	0.9	20
49	The Age-Related Hemodynamic Changes of Blood Pressure and Their Impact on the Incidence of Cardiovascular Disease and Stroke: New Evidence. <i>Journal of Clinical Hypertension</i> , 2014, 16, 87-90.	1.0	26
50	Future of Polypill Use for the Prevention of Cardiovascular Disease and Strokes. <i>American Journal of Cardiology</i> , 2014, 114, 641-645.	0.7	13
51	Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 36-43.	0.7	15
52	Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 475-483.	1.5	50
53	New insights into the true nature of the obesity paradox and the lower cardiovascular risk. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 85-94.	2.3	78
54	Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1115-1124.	0.6	7

#	ARTICLE	IF	CITATIONS
55	The Current Status of Angioplasty of Atherosclerotic Renal Artery Stenosis for the Treatment of Hypertension. <i>Journal of Clinical Hypertension</i> , 2013, 15, 694-698.	1.0	7
56	An Update on the Cardiovascular Pleiotropic Effects of Milk and Milk Products. <i>Journal of Clinical Hypertension</i> , 2013, 15, 503-510.	1.0	22
57	Treating blood pressure to prevent strokes: The age factor. <i>World Journal of Cardiology</i> , 2013, 5, 22.	0.5	6
58	Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 132-141.	2.3	31
59	Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. <i>Cardiovascular Diabetology</i> , 2012, 11, 134.	2.7	29
60	Blood Pressure Effects of High-Dose Amlodipine-Benazepril Combination in Black and White Hypertensive Patients Not Controlled on Monotherapy. <i>Drugs in R and D</i> , 2012, 12, 57-64.	1.1	0
61	Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 233-243.	1.0	22
62	Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 375-389.	1.0	4
63	The Role of Angiotensin II Receptors in Stroke Protection. <i>Current Hypertension Reports</i> , 2012, 14, 202-208.	1.5	19
64	Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors. <i>American Journal of Cardiology</i> , 2012, 109, 1681-1685.	0.7	60
65	Long-Term Efficacy and Safety of Triple-Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. <i>Journal of Clinical Hypertension</i> , 2012, 14, 149-157.	1.0	19
66	The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension. <i>Journal of Clinical Hypertension</i> , 2012, 14, 644-649.	1.0	28
67	24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 873-880.	1.0	35
68	Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. <i>American Journal of Cardiology</i> , 2011, 107, 1856-1861.	0.7	15
69	Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Postgraduate Medicine</i> , 2011, 123, 183-186.	0.9	5
70	Single-Pill Triple-Combination Therapy: An Alternative to Multiple-Drug Treatment of Hypertension. <i>Postgraduate Medicine</i> , 2011, 123, 21-31.	0.9	19
71	The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade. <i>Current Clinical Pharmacology</i> , 2010, 5, 89-95.	0.2	26
72	Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases. <i>American Journal of Cardiology</i> , 2010, 105, 849-852.	0.7	24

#	ARTICLE	IF	CITATIONS
73	Effectiveness of Lowering Blood Pressure to Prevent Stroke Versus to Prevent Coronary Events. American Journal of Cardiology, 2010, 106, 825-829.	0.7	46
74	Current Evidence on the Hemodynamic and Blood Pressure Effects of Isometric Exercise in Normotensive and Hypertensive Persons. Journal of Clinical Hypertension, 2010, 12, 721-726.	1.0	33
75	The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension. American Journal of Cardiovascular Drugs, 2010, 10, 315-320.	1.0	19
76	Safety and Tolerability of an Olmesartan Medoxomil-Based Regimen in Patients with Stage 1 Hypertension. Clinical Drug Investigation, 2010, 30, 473-482.	1.1	4
77	Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Current Medical Research and Opinion, 2010, 26, 2841-2849.	0.9	15
78	The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Drugs of Today, 2010, 46, 151.	0.7	7
79	Stopping the cardiovascular disease continuum: Focus on prevention. World Journal of Cardiology, 2010, 2, 43.	0.5	12
80	Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2009, 7, 887-895.	0.6	6
81	Efficacy and Safety of Long-Term Treatment With the Combination of Amlodipine Besylate and Olmesartan Medoxomil in Patients With Hypertension. Journal of Clinical Hypertension, 2009, 11, 475-482.	1.0	55
82	Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide. American Journal of Cardiovascular Drugs, 2009, 9, 241-251.	1.0	7
83	Irbesartan/Hydrochlorothiazide for the Treatment of Isolated Systolic Hypertension:A Subgroup Analysis of the INCLUSIVE Trial. Journal of the National Medical Association, 2009, 101, 300-307.	0.6	8
84	Current and Future Status of Beta-blockers in the Treatment of Hypertension. Clinical Cardiology, 2008, 31, 249-252.	0.7	27
85	Proactive Compared With Passive Adverse Event Recognition: Calcium Channel Blocker-Associated Edema. Journal of Clinical Hypertension, 2008, 10, 716-722.	1.0	31
86	Results of an Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Patients. Journal of Clinical Hypertension, 2008, 10, 911-921.	1.0	25
87	Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. Clinical Drug Investigation, 2008, 28, 713-734.	1.1	61
88	The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics, 2008, 30, 587-604.	1.1	247
89	Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. Clinical Therapeutics, 2008, 30, 2181-2190.	1.1	24
90	Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion, 2008, 24, 1039-1047.	0.9	40

#	ARTICLE	IF	CITATIONS
91	Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 305-314.	0.6	11
92	Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. <i>Blood Pressure Monitoring</i> , 2008, 13, 21-27.	0.4	28
93	Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: Focus on amlodipine/olmesartan combination. <i>Drugs of Today</i> , 2008, 44, 443.	0.7	4
94	The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. <i>Blood Pressure</i> , 2007, 16, 10-17.	0.7	14
95	Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. <i>Journal of Hypertension</i> , 2007, 25, 217-226.	0.3	256
96	The Pathophysiologic Role of the Brain Renin-Angiotensin System in Stroke Protection: Clinical Implications. <i>Journal of Clinical Hypertension</i> , 2007, 9, 454-459.	1.0	31
97	The Pleiotropic Effects of Angiotensin Receptor Blockers. <i>Journal of Clinical Hypertension</i> , 2006, 8, 261-268.	1.0	46
98	Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. <i>Journal of Clinical Hypertension</i> , 2006, 8, 493-501.	1.0	9
99	Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. <i>Blood Pressure Monitoring</i> , 2006, 11, 135-141.	0.4	21
100	Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases. <i>Current Clinical Pharmacology</i> , 2006, 1, 139-146.	0.2	7
101	Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension. <i>Hypertension Research</i> , 2005, 28, 555-563.	1.5	49
102	Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 657-667.	0.9	21
103	Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. <i>American Journal of Hypertension</i> , 2004, 17, 252-259.	1.0	133
104	Combination therapy with an ace-inhibitor (acei)/calcium channel blocker (ccb) for hypertensive patients non-responsive to ace-inhibitor monotherapy: an efficacy and safety trial. <i>American Journal of Hypertension</i> , 2004, 17, S102.	1.0	0
105	Olmesartan medoxomil lowers blood pressure as rapidly as amlodipine besylate in patients with mild to moderate hypertension: results of a randomized, double-blind, placebo-controlled study. <i>American Journal of Hypertension</i> , 2004, 17, S102.	1.0	0
106	Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. <i>American Journal of Hypertension</i> , 2004, 17, 590-596.	1.0	23
107	Pharmacological and Clinical Profile of Moexipril: A Concise Review. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 827-836.	1.0	9
108	Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. <i>Journal of Clinical Hypertension</i> , 2004, 6, 445-451.	1.0	14

#	ARTICLE	IF	CITATIONS
109	Stroke prevention with losartan in the context of other antihypertensive drugs. <i>Drugs of Today</i> , 2004, 40, 791.	2.4	18
110	Has the role of calcium channel blockers in treating hypertension finally been defined?. <i>Current Hypertension Reports</i> , 2003, 5, 295-300.	1.5	2
111	Pharmacological profile and clinical use of moexipril. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 345-352.	0.6	3
112	Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT). <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 335-343.	0.6	25
113	Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. <i>Journal of Clinical Hypertension</i> , 2001, 3, 283-318.	1.0	233
114	Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. <i>American Journal of Cardiology</i> , 2001, 87, 727-731.	0.7	53
115	Treatment of white coat hypertension. <i>Current Hypertension Reports</i> , 2000, 2, 412-417.	1.5	24
116	Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. <i>Current Therapeutic Research</i> , 1998, 59, 762-772.	0.5	16
117	Vascular remodeling: The role of angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 1998, 135, S21-S30.	1.2	82
118	Antihypertensive Effectiveness of a Very Low Fixed-Dose Combination of Moexipril and Hydrochlorothiazide. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 384-390.	0.8	16
119	Perindopril/Hydrochlorothiazide Dose Combinations for the Treatment of Hypertension: A Multicenter Study. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 47-52.	1.0	13
120	Clinical Utility of Long-Term Enalapril/Diltiazem ER in Stage 3-4 Essential Hypertension. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 810-815.	1.0	9
121	Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. <i>Clinical Cardiology</i> , 1997, 20, 562-568.	0.7	14
122	Sustained Blood Pressure Control with Controlled-Release Isradipine (Isradipine-ER). <i>Journal of Clinical Pharmacology</i> , 1995, 35, 239-243.	1.0	7
123	Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1060-1066.	1.0	82
124	Antihypertensive Effectiveness of Low-Dose Lisinopril-Hydrochlorothiazide Combination. <i>Archives of Internal Medicine</i> , 1994, 154, 737.	4.3	64
125	Effects of atenolol and diltiazem-ER on exercise and pressure load in hypertensive patients. <i>Clinical Cardiology</i> , 1994, 17, 670-674.	0.7	6
126	Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 479-484.	2.3	23

#	ARTICLE	IF	CITATIONS
127	Antihypertensive and Metabolic Effects of Single and Combined Atenolol Regimens. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 61-65.	1.0	23
128	Treatment of Severe Hypertension with Atenolol and Betaxolol with Once-Daily Regimens. <i>Chest</i> , 1989, 96, 499-504.	0.4	10
129	Antihypertensive Effectiveness of Amlodipine in Combination With Hydrochlorothiazide. <i>American Journal of Hypertension</i> , 1989, 2, 537-541.	1.0	32
130	Hemodynamic and Metabolic Effects of Hypomagnesemia in Spontaneously Hypertensive Rats. <i>Cardiology</i> , 1988, 75, 81-89.	0.6	25
131	Severe Reversible Azotemia From Captopril Therapy. <i>Archives of Internal Medicine</i> , 1983, 143, 437.	4.3	45
132	Effects of Diet on Exaggerated Natriuresis in Hypertension. <i>Clinical and Experimental Hypertension</i> , 1981, 3, 55-68.	1.2	2
133	Effects of Amiloride on Arterial Pressure and Renal Function. <i>Journal of Clinical Pharmacology</i> , 1980, 20, 332-337.	1.0	10
134	Renal Functional and Organic Changes Induced by Salt and Prostaglandin Inhibition in Spontaneously Hypertensive Rats. <i>Nephron</i> , 1980, 25, 151-155.	0.9	7
135	Abrupt cessation of clonidine administration: A prospective study. <i>American Journal of Cardiology</i> , 1978, 41, 1285-1290.	0.7	60
136	Hemodynamic Effects of Isometric Exercise in Normotensive Hypertensive Subjects Hypertension. <i>Angiology</i> , 1978, 29, 379-385.	0.8	11